Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMEA Biomea Fusion	$1.95 +1.6%	$1.77	$1.29 ▼ $13.07	$114.26M	-0.14	672,859 shs	590,011 shs
CMPX Compass Therapeutics	$3.49	$2.93	$1.25 ▼ $4.08	$482.61M	1.49	1.47 million shs	702,510 shs
IMAB I-Mab	$4.16 -2.1%	$3.03	$0.60 ▼ $5.90	$347.06M	1.38	4.86 million shs	1.40 million shs
IVA Inventiva	$6.19 -2.5%	$3.65	$1.53 ▼ $6.50	$607.46M	0.73	47,818 shs	189,339 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMEA Biomea Fusion	+1.56%	+6.56%	+17.47%	+35.42%	-74.14%
CMPX Compass Therapeutics	0.00%	+15.56%	+14.43%	+63.08%	+193.28%
IMAB I-Mab	-2.12%	-18.27%	+104.93%	+220.00%	+255.56%
IVA Inventiva	-2.52%	+38.48%	+100.97%	+97.70%	+158.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMEA Biomea Fusion	3.5957 of 5 stars	4.6	3.0	2.0	2.5	0.6
CMPX Compass Therapeutics	2.1759 of 5 stars	3.6	1.0	2.2	3.3	0.0
IMAB I-Mab	2.957 of 5 stars	3.5	5.0	2.8	1.7	0.0
IVA Inventiva	3.0169 of 5 stars	3.4	5.0	2.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMEA Biomea Fusion	3.17	Buy	$14.80	658.97% Upside
CMPX Compass Therapeutics	3.10	Buy	$12.89	269.31% Upside
IMAB I-Mab	3.00	Buy	$7.00	68.27% Upside
IVA Inventiva	2.83	Moderate Buy	$13.00	110.02% Upside

Current Analyst Ratings Breakdown

Latest BMEA, IVA, CMPX, and IMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2025	IMAB I-Mab	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$8.00
8/28/2025	IMAB I-Mab	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/28/2025	BMEA Biomea Fusion	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
8/28/2025	BMEA Biomea Fusion	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
8/27/2025	IVA Inventiva	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$26.00
8/27/2025	IVA Inventiva	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$26.00
8/21/2025	IMAB I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
8/20/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.00 ➝ $6.00
8/12/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
8/12/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
8/11/2025	BMEA Biomea Fusion	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $7.00

(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$0.46 per share	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	$0.67 per share	N/A
IMAB I-Mab	$3.89M	87.33	N/A	N/A	$2.41 per share	1.73
IVA Inventiva	$9.95M	59.51	N/A	N/A	($1.21) per share	-5.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMEA Biomea Fusion	-$138.43M	-$3.03	N/A	N/A	N/A	N/A	-243.95%	-140.74%	11/4/2025 (Estimated)
CMPX Compass Therapeutics	-$49.38M	-$0.45	N/A	N/A	N/A	N/A	-53.11%	-46.14%	11/11/2025 (Estimated)
IMAB I-Mab	-$22.23M	N/A	0.00	N/A	N/A	N/A	-19.65%	-18.58%	11/13/2025 (Estimated)
IVA Inventiva	-$199.34M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/25/2025 (Estimated)

Latest BMEA, IVA, CMPX, and IMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/25/2025	Q2 2025	IVA Inventiva	-$0.41	N/A	N/A	N/A	N/A	N/A
8/20/2025	Q2 2025	IMAB I-Mab	-$0.10	-$0.07	+$0.03	-$0.07	N/A	N/A
8/11/2025	Q2 2025	CMPX Compass Therapeutics	-$0.13	-$0.14	-$0.01	-$0.14	N/A	N/A
8/5/2025	Q2 2025	BMEA Biomea Fusion	-$0.59	-$0.51	+$0.08	-$0.51	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
IMAB I-Mab	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMEA Biomea Fusion	N/A	3.68	3.68
CMPX Compass Therapeutics	N/A	7.66	7.66
IMAB I-Mab	N/A	22.82	22.82
IVA Inventiva	N/A	0.92	0.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMEA Biomea Fusion	96.72%
CMPX Compass Therapeutics	68.43%
IMAB I-Mab	38.38%
IVA Inventiva	19.06%

Insider Ownership

Company	Insider Ownership
BMEA Biomea Fusion	18.42%
CMPX Compass Therapeutics	29.80%
IMAB I-Mab	22.10%
IVA Inventiva	32.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMEA Biomea Fusion	50	59.51 million	48.55 million	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
IMAB I-Mab	380	81.66 million	63.61 million	Optionable
IVA Inventiva	100	95.66 million	65.05 million	Not Optionable

BMEA, IVA, CMPX, and IMAB Headlines

Recent News About These Companies

Piper Sandler Begins Coverage on Inventiva (NASDAQ:IVA)

August 30 at 2:10 AM | americanbankingnews.com

Inventiva (NASDAQ:IVA) Hits New 12-Month High - What's Next?

August 29 at 11:14 AM | marketbeat.com

How Much Upside is Left in Inventiva (IVA)? Wall Street Analysts Think 100.79%

August 29 at 10:56 AM | zacks.com

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 29 at 7:34 AM | marketbeat.com

Inventiva (NASDAQ:IVA) Trading 4.3% Higher - What's Next?

August 28 at 2:05 AM | marketbeat.com

Inventiva initiated with an Overweight at Piper Sandler

August 27 at 8:39 PM | msn.com

Inventiva surges as Piper Sandler issues bullish view citing lead asset

August 27 at 8:39 PM | msn.com

Short Interest in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Drops By 72.9%

August 17, 2025 | marketbeat.com

Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

August 12, 2025 | finance.yahoo.com

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Update

August 3, 2025 | marketbeat.com

Half-Year Review of Inventiva’s Liquidity Contract with Kepler ...

August 2, 2025 | morningstar.comM

Inventiva Announces Preliminary First-Half 2025 Financial Results

July 31, 2025 | theglobeandmail.com

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

July 31, 2025 | globenewswire.com

INVENTIVA: Inventiva Reports Preliminary 2025 First-Half Financial Information

July 30, 2025 | finanznachrichten.de

Inventiva Reports Preliminary 2025 First-Half Financial Information¹

July 30, 2025 | finance.yahoo.com

Inventiva appoints new R&D president and regulatory affairs executive

July 11, 2025 | investing.com

Inventiva names Jason Campagna as President of R&D and Chief Medical ...

July 11, 2025 | finance.yahoo.com

Inventiva Strengthens Leadership Team Ahead of Key MASH Drug Milestones

July 10, 2025 | yahoo.com

Inventiva reshuffles leadership as it pushes lanifibranor closer to approval

July 10, 2025 | thepharmaletter.comT

Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance

July 9, 2025 | globenewswire.com

INVENTIVA: Inventiva receives $10 million milestone payment from CTTQ

July 8, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BMEA, IVA, CMPX, and IMAB Company Descriptions

Biomea Fusion NASDAQ:BMEA

$1.95 +0.03 (+1.56%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$1.94 -0.01 (-0.77%)

As of 08/29/2025 07:10 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Compass Therapeutics NASDAQ:CMPX

$3.49 0.00 (0.00%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$3.52 +0.03 (+1.00%)

As of 08/29/2025 07:27 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

I-Mab NASDAQ:IMAB

$4.16 -0.09 (-2.12%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$4.24 +0.08 (+1.80%)

As of 08/29/2025 07:27 PM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Inventiva NASDAQ:IVA

$6.19 -0.16 (-2.52%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$6.24 +0.05 (+0.81%)

As of 08/29/2025 07:23 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time